82956
EPN · Supratentorial EPN
Clinical attributes
From the source cohort, normalized into canonical keys plus the project's native columns.
- cancer_type
- EPN
- cancer_type_detailed
- —
- subtype
- Supratentorial EPN
- cancer_type
- EPN
- subtype
- Supratentorial EPN
- age_years
- 2
- fusion
- ZFTA_RELA
- e1_e2
- E1
- umap1_2d
- -3.046833854
- umap2_2d
- 1.221564776
- umap1_3d
- 0.329512546
- umap2_3d
- 2.971384258
- umap3_3d
- -2.434326173
- dataset
- EPN-Felix
GSVA pathway preview (50 Hallmark scores)
Top 10 most elevated and top 10 most suppressed Hallmark pathways for this sample.
Top 10 elevated
- OXIDATIVE_PHOSPHORYLATION+0.530
- PROTEIN_SECRETION+0.410
- MYC_TARGETS_V1+0.380
- UNFOLDED_PROTEIN_RESPONSE+0.380
- DNA_REPAIR+0.370
- CHOLESTEROL_HOMEOSTASIS+0.310
- INTERFERON_ALPHA_RESPONSE+0.300
- MTORC1_SIGNALING+0.290
- FATTY_ACID_METABOLISM+0.280
- MYC_TARGETS_V2+0.270
Top 10 suppressed
- EPITHELIAL_MESENCHYMAL_TRANSITION-0.370
- KRAS_SIGNALING_UP-0.320
- HYPOXIA-0.290
- KRAS_SIGNALING_DN-0.290
- ALLOGRAFT_REJECTION-0.230
- INFLAMMATORY_RESPONSE-0.220
- APICAL_JUNCTION-0.210
- IL6_JAK_STAT3_SIGNALING-0.200
- COMPLEMENT-0.190
- PANCREAS_BETA_CELLS-0.170
Patient twins — nearest pathway neighbors
10 samples closest to this one in 50-dim pathway space, drawn from the Pathway Atlas. Cosine similarity = 1 means identical pathway state.
9 twins match this tumor's tissue · 1 come from a different tissue of origin
| # | Sample | Cancer type | Subtype | cos similarity |
|---|---|---|---|---|
| 1 | F2FCC449-3487-474C-82A6-8F2ED71E41BC | — | — | 0.828 |
| 2 | MNG434 | — | — | 0.817 |
| 3 | EA6A086B-F655-47E8-9E70-8A2D36FC2AE1 | — | — | 0.807 |
| 4 | A0DA6087-9D43-41F9-8569-9F9320E4A9E8 | — | — | 0.802 |
| 5 | SJBT031392_D1.RNA-Seq | EPN | EPN Tumor | 0.795 |
| 6 | MNG570 | — | — | 0.784 |
| 7 | BS_CZ3NA7KV | Supratentorial Ependymoma | — | 0.782 |
| 8 | A6FB1BEE-0D36-480C-8619-1FA82583FCD1 | — | — | 0.777 |
| 9 | b2b4cc41-5760-4463-bcde-16115ceb12c2 | — | — | 0.773 |
| 10 | SRR6013598 | — | cohortA4 | 0.773 |
Per-pathway drug coverage
For each elevated pathway in this tumor, the best-reversing drug across the catalog. Uncovered pathways = unmet need at pathway level for this one patient.
0 of 27 elevated pathways have at least one drug that meaningfully reverses them.
| Pathway (elevated) | tumor score | Best drug | reversal magnitude |
|---|---|---|---|
| OXIDATIVE_PHOSPHORYLATION | 0.530 | Remibrutinib | — uncovered |
| PROTEIN_SECRETION | 0.410 | Remibrutinib | — uncovered |
| MYC_TARGETS_V1 | 0.380 | Inavolisib | — uncovered |
| UNFOLDED_PROTEIN_RESPONSE | 0.380 | Idelalisib | — uncovered |
| DNA_REPAIR | 0.370 | Idelalisib | — uncovered |
| CHOLESTEROL_HOMEOSTASIS | 0.310 | Remibrutinib | — uncovered |
| INTERFERON_ALPHA_RESPONSE | 0.300 | Inavolisib | — uncovered |
| MTORC1_SIGNALING | 0.290 | Inavolisib | — uncovered |
| FATTY_ACID_METABOLISM | 0.280 | Inavolisib | — uncovered |
| MYC_TARGETS_V2 | 0.270 | Idelalisib | — uncovered |
| HEME_METABOLISM | 0.260 | Temsirolimus | — uncovered |
| REACTIVE_OXYGEN_SPECIES_PATHWAY | 0.260 | Inavolisib | — uncovered |
| ADIPOGENESIS | 0.250 | Inavolisib | — uncovered |
| PI3K_AKT_MTOR_SIGNALING | 0.240 | Inavolisib | — uncovered |
| UV_RESPONSE_UP | 0.160 | Idelalisib | — uncovered |
| ANDROGEN_RESPONSE | 0.130 | Inavolisib | — uncovered |
| UV_RESPONSE_DN | 0.130 | Inavolisib | — uncovered |
| WNT_BETA_CATENIN_SIGNALING | 0.120 | Inavolisib | — uncovered |
| P53_PATHWAY | 0.110 | Idelalisib | — uncovered |
| SPERMATOGENESIS | 0.100 | Inavolisib | — uncovered |